Natco Pharma (NSE: NATCOPHARM) is an Indian pharmaceutical company known for producing affordable generic versions of expensive drugs. The company has built a reputation for challenging patent monopolies - sometimes winning, sometimes losing, but always generating headlines.
The Business Model
Natco generates approximately 4,800 crore in annual revenue from generic drugs, active pharmaceutical ingredients, and niche formulations. The company targets first-to-market opportunities when patents expire on blockbuster drugs. This creates lumpy revenue - a single successful patent challenge can generate hundreds of crores.
The Copaxone Marathon
Natco spent more than a decade fighting Teva over Copaxone, the multiple sclerosis drug, alongside its US partner. Wins and reversals in district court and the Federal Circuit eventually gave way to limited generic entry years after the patent cliff should have arrived.
The episode cuts both ways. A protected share of a billion-dollar drug is a windfall, but the legal burn and delay show why patent challenge economics need a portfolio, not a single bet.
The Lenalidomide Windfall
Generic Revlimid was the sector prize of the decade. Under settlement terms, Natco and a small group of entrants could sell limited volumes from March 2022, with volume caps lifting from January 2026. The FY2023 revenue jump came largely from that capped launch.
The schedule defines the trade. Removing the caps converts a shortage into a competition just as more entrants pile in. Windfalls like this fund the company and then end; price erosion follows.
Key Products
Natco partnered with Arrogan (now Allergan) for generic Sovaldi (hepatitis C). They sell generic Lenalidomide (Revlimid) in India. The company's CopaGeist (for glioblastoma) was the first generic of Avastin approved in India. Each launch contributes disproportionate margin.
Financial Performance
Revenue growing 10-15 percent annually. Net margins around 20 percent - high for Indian pharma. P/E at approximately 25x. Stock trades around 1,100 with the annual band running from 750 to 1,350.
The Risk Sheet
Three risks are structural. USFDA inspections can idle specific plants, and warning letters freeze new approvals from affected sites. US generic price erosion runs 5-10 percent a year on average, punishing any gap in new launches. And because revenue concentrates in a handful of lumpy products, a single adverse court ruling can gut a year of earnings.
Domestic price controls on essential medicines cap the India floor. None of these risks is hidden; all of them show up in the stock's habit of moving 8 percent on a Friday afternoon.
The Quarterly Checklist
Track the US revenue share, the count of new ANDA approvals, updates on pending patent litigation, and the inspection calendar for the Hyderabad and Chennai area plants. Litigation trackers and FDA dockets are public; the work is free, just tedious.
Trading on Lannapay
On Lannapay, Natco trades on streaming prices. The stock moves on drug approval news, patent litigation outcomes, and USFDA inspection reports. Use bracket orders around legal decisions. Support at 980. Resistance at 1,180 then 1,350.
Natco rewards event-driven traders. Set alerts on FDA filings and patent challenge outcomes. These binary events create the biggest single-day moves.
Trading the Calendar
Run Natco as an event book on Lannapay. Pre-position small brackets before scheduled court rulings and FDA decision dates, framed by the 980 support and the 1,180 and 1,350 resistance levels, and sell a third of any announcement spike within the first hour - event liquidity fades fast, and gaps close slowly. Between events the stock drifts with the pharma index, so there is no edge in holding full size through quiet months. Build a list of pending patent challenges with dates, size each event at 0.5-1 percent risk, and let the lumpy revenue model work for you instead of surprising you.